Patrick Trucchio
Recent Articles
What Do Analysts Think About the Biopharma Set on Transforming Psychiatry 04/09/2026
Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates.
Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing 03/25/2026
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3.
2 Key Catalysts Ahead for Developer of Psych Drugs 10/28/2025
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report.
Biopharma's New MASH Drug Has Two MOAs 10/15/2025
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report.
New Therapy for AATD Could be Best in Class 04/08/2025
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report.
PDUFA Date Nearing for New PSVT Drug 03/19/2025
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report.
Analyst Says CA Pharma Underappreciated by Investors 07/23/2024
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors.
